]-HI) within hepatic endosomes was undertaken to determine whether the endosomal compartment represents a physiological site for the removal of Arg residues and conversion of Arg-extended insulins into fully processed human insulin. Methods The metabolic fate of arginyl-insulins has been studied using the in situ rat liver model system following ligand administration to rats and cell-free hepatic endosomes. Results While the kinetics of insulin receptor endocytosis after the administration of arginyl-insulins were similar to those observed using human insulin, a more prolonged concentration of endosomal insulin receptor was observed in response to [Arg A0 ]-HI. [Arg A0 ]-HI induced a marked increase in the phosphotyrosine content of endosomal insulin receptor, coinciding with a more sustained endosomal association of growth factor receptor-bound protein 14 (GRB14), and a higher and prolonged activation of mitogen-activated protein kinase pathways. At acidic pH, the endosomal cathepsin D rapidly degraded insulin peptides with similar binding affinity, and generated comparable intermediates for both arginyl-insulins without affecting amino and carboxyl arginyl-peptide bonds. At neutral pH, hepatic endosomes fully processed [Arg A0 ]-HI into mature human insulin while no conversion was observed with [Arg B31 -Arg B32 ]-HI. The neutral endosomal Arg-convertase was sensitive to bestatin, immunologically distinct from insulin-degrading enzyme, nardilysin or furin, and was potentially related to aminopeptidase-B-type enzyme. Conclusions/interpretation The data describe a unique processing pathway for the endosomal proteolysis of [Arg A0 ]-HI which involves the removal of Arg A0 and subsequent generation of mature human insulin through an uncovered neutral Arg-aminopeptidase activity. The endosomal conversion of [Arg A0 ]-HI into human insulin might extend the insulin receptor signalling at this locus.
Introduction
Endoproteolytic cleavage of protein prohormones often generates intermediates extended at the C-terminus by ArgArg or Lys-Arg, the removal of which by carboxypeptidases is an important step in the complete maturation of polypeptide hormones. In the secretory granules of pancreatic beta cells, conversion of proinsulin to insulin occurs with the removal of the C-peptide connecting the C-terminus of insulin B-chain to the N-terminus of the insulin A-chain [1] . The conversion of proinsulin to insulin involves endoproteolytic cleavages on the carboxyl side of the basic Arg 31 -Arg 32 and Lys
64
-Arg 65 bonds by the proprotein convertases PC3 and PC2; the remaining C-terminal Arg residues are then removed by carboxypeptidase H [2] . During the conversion of proinsulin and the subsequent release of mature insulin, C-peptide and free Arg and Lys into the blood circulation, incompletely cleaved intermediates (des-[64,65]-and des- [31, 32] proinsulins, mono-and diarginyl-insulins) as well as intact proinsulin were concomitantly released in plasma with levels being possibly increased under pathological states conditions [3] . It has been proposed that proinsulin, which is normally processed in secretory granules and released via the regulated pathway, may also be processed-albeit less efficiently-by target tissue (hepatic parenchyma) [4] [5] [6] . Thus, rat liver endosomal extracts have been shown to process proinsulin within the C-peptide region at the dibasic motifs 31-32 and 64-65 [4] [5] [6] . Comparably, rat hepatoma Fao cells stably transfected with proinsulin have been shown to process proinsulin intracellularly, generating split forms of proinsulin as well as fully processed insulin [5] .
Human diarginyl-insulin ([Arg
B31
-Arg B32 ]-HI) is one of the major proinsulin intermediates and differs from native insulin by two remaining Arg at the C-terminus of the Bchain [7, 8] . [Arg ]-HI has almost identical insulin receptor (IR) binding characteristics and full biological activity in vitro as compared with mature human insulin (HI) [7] . Human monoarginyl-insulin ([Arg   A0 ]-HI), another potential arginyl-insulin intermediate, contains an additional Arg at the N-terminus insulin A-chain and displays approximately two-thirds of the binding and biological activity of HI [9, 10] . The reduced biological activity of [Arg A0 ]-HI can be attributed, at least in part, to modifications in the charge surface and changes in the relative orientation of the two helices in the A-chain [11, 12] .
The question then arises as to whether the endosomal compartment of hepatic target tissue should be considered as an alternative processing site for the removal of basic residues from internalised Arg-extended peptides. Consequently, the present study has attempted to evaluate the physiological relevance of hepatic endosomes for the conversion of monoand diarginyl-insulins into mature insulin. Reverse phase-HPLC (RP-HPLC) and mass spectrometry analyses revealed that production of mature insulin occurs at pH 7 during incubation of [Arg A0 ]-HI with hepatic endosomes, while no conversion was observed using [Arg B31 -Arg B32 ]-HI under these same conditions. Using immunological criteria and the Arg-MCA fluorescence assay, we show also that the neutral proteolytic activity which removes the single N-terminal Arg in [Arg A0 ]-HI is a bestatin-sensitive aminopeptidase activity that is possibly related to aminopeptidase-B (AP-B) [13] . Finally, while both arginyl-insulins induced the endocytosis and tyrosine phosphorylation of the IR in vivo, only the [Arg   A0 ]-HI treatment resulted in a higher extent and duration of IR tyrosine phosphorylation and a prolonged residence time of IR at the endosomal locus.
Methods
Peptides, antibodies, protein determination and materials HI [Arg A0 ]-HI and Z-L-Arg 7-amido-4-methylcoumarine hydrochloride (Arg-MCA) were purchased from Sigma (St Louis, MO, USA). [Arg B31 -Arg B32 ]-HI was supplied by Eli Lilly (Indianapolis, IN, USA) and obtained from R. E. Isaac (University of Leeds, Leeds, UK). HI was radioiodinated as described previously [14] . Polyclonal antibody to SHCadaptor protein (SHC) was obtained from J. J. M. Bergeron (McGill University, Montreal, Canada). Polyclonal IgG preparations against the human IR-β subunit and rat insulin receptor substrate-1 (IRS-1), and monoclonal antiphosphotyrosine (PY) (clone 4G10) were purchased from UBI (Lake Placid, NY, USA). Monoclonal IgG against AP-B (clone 4E1) was from Sigma. Polyclonal IgG against human phospho-p44/42 mitogen-activated protein (MAP) kinase and rat p44/42 MAP kinase proteins were from Cell Signaling Technology (Danvers, MA, USA). Polyclonal antibody against growth factor receptor-bound protein 14 (GRB14) has been previously described [15] . Rabbit antimouse cathepsin D R291 [16, 17] , sheep anti-human cathepsin D M8147 [16, 17] and rabbit anti-rat cathepsin B 7183 [18] were obtained from J. S. Mort (Shriners Hospital for Crippled Children, Montreal, Canada). Monoclonal antibody directed against insulin-degrading enzyme (IDE) [19, 20] was obtained from R. A. Roth (Stanford University, Stanford, CA, USA). Polyclonal antibody to nardilysin was obtained from L. B. Hersh (University of Kentucky, Lexington, KY, USA). Polyclonal antibody against human furin was from Santa Cruz Biotechnology (Santa Cruz, CA, USA) [21, 22] . The protein content was determined by the method of Lowry et al. [23] . All other chemicals were obtained from commercial sources and were of reagent grade.
Animals
In vivo procedures were approved by the Institutional Committee for the Use and Care of Experimental Animals. Male Sprague-Dawley rats, body weight 180-200 g, were obtained from Charles River France (St Aubin Les Elbeufs, France) and fasted for 18 h prior to sacrifice. Native insulin peptides (15 μg/100 g body weight) in 0.4 ml of 0.15 mol/l NaCl was injected within 5 s into the penile vein under light anaesthesia with ether.
Rat liver subcellular fractionation Subcellular fractionation was performed using established procedures as previously described. Nuclear, mitochondrial lysosomal, microsomal and cytosolic fractions were isolated by differential centrifugation [14, 16-19, 21, 22, 24, 25] . The endosomal fraction (EN) was isolated by discontinuous sucrose gradient centrifugation and collected at the 0.25-1.0 mol/l sucrose interface [14, 16-19, 21, 22, 24, 25] . Soluble endosomal extract (ENs) was isolated from the EN fraction as previously described [14, 16-19, 21, 22, 24, 25] .
Immunoblot analysis Electrophoresed samples were transferred as described previously [16] [17] [18] [19] [20] [21] [22] and the membranes were then incubated with primary antibody (antibodies against SHC diluted 1:5000, IR-β subunit diluted 1:1000, phospho-p44/42 MAP kinase diluted 1:350, p44/42 MAP kinase diluted 1:350, GRB14 diluted 1:500, IRS-1 diluted 1:1000, nardilysin diluted 1:1000, PY diluted 1:2500 or AP-B diluted 1:200). The bound immunoglobulin was detected using horseradish peroxidase-conjugated goat anti-rabbit or anti-mouse IgG. Quantification of protein signals were done by scanning densitometry using the analysis program Scion Image (Frederick, MA, USA).
Immunodepletion studies ENs was immunodepleted of endosomal proteases prior to the digestion step by incubating ENs (0.15 mg/ml) with antibodies coated onto protein G-Sepharose beads for 16 h at 4°C in 800 μl of 20 mmol/l sodium phosphate buffer (pH 7). The fractions were then centrifuged for 5 min at 10,000×g, and the resultant immunodepleted supernatant fractions were adjusted to pH 4 with citrate-phosphate buffer and used in the insulin-peptide degradation assay and then immediately assayed by RP-HPLC. ]-HI in 0.1 mol/l citratephosphate buffer, pH 4, for 10 min at 37°C. The amount of radiolabelled HI-degraded was assayed by precipitation with 2 ml of ice-cold 10% trichloroacetic acid (TCA) for 2 h at 4°C. The samples were then centrifuged at 10,000×g for 20 min at 4°C, and the supernatant fractions and pellets evaluated for their radioactive content.
In vitro proteolysis of insulin peptides by endosomes
HPLC separation of insulin peptides and mass spectrometry RP-HPLC was performed using a Beckman Coulter (Fullerton, CA, USA) System Gold model 127 as previously described [16-18, 21, 26] . Eluates were monitored online for absorbance at 214 nm with a LC-166 spectrophotometer (Beckman Coulter).
Samples were prepared and analysed using ion spray mass spectrometry and HPLC-electron spray ionisation mass spectrometry coupling as previously described [6, 16, 21, 26, 27] .
Arginine-aminopeptidase assay Arg-aminopeptidase activity of isolated endosomes was assayed using Arg-MCA substrate [28] . EN (1.5 mg/ml) was incubated with Arg-MCA (200 μmol/l) in 50 mmol/l Tris-HCl, pH 7.4, containing 0.15 mol/l NaCl. The suspensions were immediately placed in the spectrofluorometer, and fluorescence intensities (365/450 nm excitation/emission) were recorded at 37°C for 1-8 h.
Statistics Data are expressed as mean ±SD. Statistical evaluations were performed by Student's t test. Differences between data groups were considered statistically significant if p<0.05.
Results
In vivo effects of arginyl-insulins on IR trafficking and signalling Following the i. v. injection of a single receptorsaturating dose of insulin peptides, the relative levels of IR in rat liver endosomal fractions were measured by immunoblotting with antibody raised to IR-β subunit (Fig. 1a , α-IR-β blot). An increase in IR-β subunit was observed 2 min after administration of either insulin peptides, with both showing identical initial internalisation kinetics (up to 2 min). In response to HI and [Arg B31 -Arg B32 ]-HI, the level attained was maximal at 2 min with a return to background levels observed after 60 min. However, in response to [Arg A0 ]-HI, an accumulation of IR-β was observed in the EN fractions for up to 5 min before decreasing with time. Tyrosine-phosphorylated IR was detected 2 min after administration of either of the three ligands (Fig. 1a , α-PY blot). A higher and more prolonged PY content was observed for [Arg A0 ]-HI at 5 min post injection with the level remaining elevated up to 30 min.
To study the effect of arginyl-insulin administration on protein adaptor compartmentalisation, rat-liver-derived EN fractions were assayed for IRS-1, SHC and GRB14 content after ligand injection (Fig. 1a , three lower blots). All three protein adaptors were detected in EN fractions isolated from control rats (lanes -). Administration of HI [24] or arginyl-insulins did not cause detectable changes in the levels of IRS-1 or SHC isoforms at the endosomal locus. In contrast, the three ligands led to a rapid increase in the content of the molecular adaptor GRB14 within EN fractions [15] . Endosomal association of GRB14 was more sustained after the administration of [Arg A0 ]-HI, which paralleled its effect on phosphorylated IR-β content.
MAP kinase activity was then assayed in response to ligand administration by immunoblotting cytosolic fractions with antibodies against total or phosphorylated p44/42 MAP kinase proteins (Fig. 1b) The effect of various protease inhibitors on the acidic arginyl-insulin-degrading activity contained in hepatic endosomes was next examined by RP-HPLC analysis (Fig. 3a,b) . The proteolytic activity directed against both arginyl-insulins at pH 4 was inhibited by pepstatin-A, an inhibitor of aspartic acid proteases.
The inhibition of arginyl-insulin-degrading activity by pepstatin-A suggested cathepsin D as a likely candidate for this activity. We therefore used well-characterised antibodies to mature cathepsin D and its proform [16, 17] to deplete cathepsin D from ENs (Fig. 3a,c) . Quantitative immunoprecipitation of cathepsin D using antibodies directed against the mouse (R291) and human enzyme (M8147) removed more than 80% of the endosomal proteolytic activity directed towards both arginyl-insulins as assessed by RP-HPLC (Fig. 3a, lower panels, and c) . Immunodepletion of ENs with antibodies to either cathepsin B [18] , IDE [19, 20] , furin [21, 22] or nardilysin failed to remove the arginyl-degrading activity (Fig. 3c) .
Substrates of the same protease would be expected to compete with each other for the enzyme binding site. We therefore used a competition assay to evaluate the ability of native arginyl-insulins to inhibit degradation of the radio- ) . The major peptide pools, numbered sequentially 1-9, were collected and subjected to mass spectrometry analyses (see Table 1 ). (Fig. 3d) . As reported previously [16, 26] , HI was found to inhibit 125 I-labelled HI proteolysis by ENs in a dosedependent manner with an IC 50 of 2 × 10 −5 mol/l. Native arginyl-insulins were found to compete for proteolysis of radiolabelled HI in a manner similar to that observed for HI (IC 50 3×10 −5 and 1×10 −5 mol/l, respectively).
Sites of cleavage of arginyl-insulin intermediates To determine whether cathepsin D is capable of cleaving arginylinsulins at the same primary sites as those observed with HI [16, 26] , each of the major HPLC peaks generated after a 2.5 h incubation at pH 4 (see Fig. 2b,d ) was analysed using mass spectrometry ( ]-HI at neutral pH Hepatic endosomes are known to contain neutral peptidases such as IDE [29] , furin [21, 22, 30] and neutral glucagonase activity [21] . Therefore, we evaluated the ability of hepatic endosomes to process arginyl-insulins at neutral pH (Fig. 5a, b) using RP-HPLC analyses. While no processing was observed using [Arg B31 -Arg B32 ]-HI (results not shown), a significant rate of [Arg A0 ]-HI hydrolysis was detected with generation of the mature HI peptide (mass analysis 5,806 Da). The production of HI was strongly inhibited by bestatin, an inhibitor of aminopeptidases, and metal-chelating agents (EDTA and 1,10-phenanthroline).
Nardilysin and aminopeptidase B (AP-B), two neutral arginine-peptidases [21, 31] , represent candidate proteases Fig. 2b, d for the production of HI from internalised [Arg A0 ]-HI. Consequently, we attempted to evaluate the contribution of these proteases to the endosomal degradation of [Arg A0 ]-HI by immunodepletion of EN (Fig. 5b) , or assessment of their content in hepatic endosomes by immunoblot analysis (Fig. 5c) . Immunoprecipitation with antibodies to IDE, nardilysin or furin failed to remove the neutral Argdegrading activity from EN (Fig. 5b) . Immunoblot analyses of rat liver homogenate, nuclear, large granule, microsomal and cytosolic fractions from control rats (Fig. 5c, upper  blots) , and endosomal fractions from non-injected (lane -) or monoarginyl-insulin-injected rats (lanes EN/[Arg A0 ]-HI) (Fig. 5c, lower blot) revealed that both the cytosolic and microsomal fractions contained the highest concentration of nardilysin and AP-B, suggesting that both proteases displayed a dual soluble and particulate location in rat liver. However, in purified EN, nardilysin was undetectable (results not shown), whereas a small but detectable presence of AP-B was found within hepatic endosomes isolated from control and monoarginyl-insulin-injected rats (Fig. 5c) .
We subsequently used Arg-MCA from which a fluorescent product is generated by a single cleavage (Fig. 5d) . When EN fractions isolated from control rat livers were incubated at pH 7 with 200 μmol/l Arg-MCA, significant fluorescence intensities were detected after 15 and 30 min of incubation. No hydrolysis of Arg-MCA was detected under conditions of aminopeptidase inhibition (presence of bestatin). ]-HI may follow a specific proteolytic activating pathway which operates at an early stage of endocytosis and extends the IR signalling. Hence, based on the amount of proinsulin intermediates circulating in the blood, which account for 10-30% of insulin immunoreactivity in the fasting state [1, 32] , and in the light of the in vivo effects of arginylinsulins on hepatic IR signalling (this study), it may be hypothesised that arginyl-insulins fully participate in the insulinic action in hepatic target tissue.
The influence of endosomal proteolysis of insulin on IR trafficking and signal transduction has been previously inferred from a comparison of IR internalisation in liver parenchyma after in vivo challenge with receptor-saturating doses of insulin, high-affinity insulin analogues [14, 24, 26] or proinsulin [6] . While insulin was subject to rapid endosomal ligand dissociation and degradation [16, 19, 33] , reduced in vivo and cell-free endosomal processing was observed with the H2-analogue [14, 24, 26] and proinsulin [6] . An altered IR phosphotyrosine profile was also observed at the endosomal locus, with this process being higher (H2-analogue) and of longer duration (H2-analogue and proinsulin) [6, 14, 24] . Using [Arg A0 ]-HI as a ligand, an increase in the phosphorylation state of endosomal IR was observed which resembled that of the IR in response to the high-affinity H2-analogue [14, 24] . Moreover, an increase in IR transit through endosomes was observed with [Arg ]-HI longer than that of HI. Interestingly, as previously reported for the protease-resistant H2-analogue [15, 24] , [Arg A0 ]-HI induced an increase in the kinetics of MAP kinase activation and a more sustained association of GRB14 with the hepatic endosomes.
To test whether endosomal processing of [Arg A0 ]-HI may influence IR trafficking and signalling at the endosomal locus, a detailed proteolysis study of arginyl-insulins was undertaken using a soluble endosomal lysate and RP-HPLC coupled to mass spectrometry analyses. In liver parenchyma the endosomal degradation of internalised insulin is thought to occur after acidification of the endosomal lumen by the aspartic acid protease cathepsin D which hydrolyses HI at Phe B24 -Phe B25 and Phe B25 -Tyr B26 peptide bonds [16, 19, 26] . Consistent with our previous studies, we have concluded in the present work that the endosomal acidic proteolytic activity directed towards the arginyl-insulins was comparable with that of cathepsin D, as indicated by the following observations: (1) the inhibitor profile of the endosomal proteolytic activity was similar to that of endosomal acidic insulinase activity and cathepsin D [16] ; (2) immunodepletion of cathepsin D from ENs led to a loss of arginyl-insulin-degrading activity; and (3) the arginyl-insulins were found to inhibit 125 Ilabelled Tyr A14 -HI degradation by ENs, confirming that the arginyl-insulins and HI share a common binding site on cathepsin D. On the basis of IC 50 values, competition studies revealed that mature insulin and arginyl-insulins displayed nearly equivalent affinity for the endosomal acidic insulinase (cathepsin D). Finally, RP-HPLC and mass spectrometry analyses of the degradation products generated from arginyl-insulins by endosomal acidic insulinase (cathepsin D) revealed a pattern of cleavage sites similar to those observed using authentic insulin [16, 26] . The data suggest that the altered endosomal tyrosinephosphorylation state of the IR-β subunit observed after [Arg A0 ]-HI treatment did not arise from qualitative differences of ligand processing at acidic pH.
Previous studies have shown that proteases active at neutral pH are present in endosomes and that endosomal vesicles degrade various internalised ligands prior to the acidification step [34, 35] . Thus, it has been proposed that the initial step in insulin degradation occurs within hepatic endosomes at neutral pH and involves IDE, a neutral metalloendopeptidase [29] . Comparably, an endosomal membrane glucagonase activity transforms glucagon into miniglucagon at pH 7 [21] . We have also recently shown that rat hepatic endosomes contain a luminal truncated furin that cleaves the Arg 193 -Ser 194 peptide bond in the connecting A-B region of internalised diphtheria toxin at neutral pH [22] . We have now extended these observations to [Arg A0 ]-HI and suggest that proinsulin intermediates possessing flanking sequences such as basic residues may undergo endosomal processing via a sequential degradation pathway beginning early, prior to organelle acidification, and following later under acidic conditions.
Our present data clearly show that [Arg A0 ]-HI is susceptible to hydrolysis by a neutral Arg-aminopeptidase present in hepatic endosomes. Under our experimental conditions, fully processed HI was the unique product formed by the action of a bestatin-sensitive metallo-aminopeptidase. Using an alternative approach in which hydrolysis of the Nterminal Arg-peptide bond was measured by the generation of fluorescent product from the non-fluorescent substrate Arg-MCA, we have confirmed that Arg-aminopeptidase is endosomally active in rat liver. Nardilysin and AP-B, two Arg-convertases that exhibit multiple physiological functions, have been reported to be present and active in hepatocytes. Nardilysin, a metallopeptidase, preferentially cleaves Arg bonds within paired basic residues [36] while AP-B catalyses the cleavage of Arg at the N-terminus of peptides [13] . Using immunoblot analyses we showed that a small but detectable amount of AP-B was present in hepatic endosomes while nardilysin was absent from this compartment. We were unable to test directly the role of AP-B in the endosomal processing of internalised [Arg A0 from monoarginyl-insulin was observed. Thus, the removal of Arg from Arg-extended peptides within the endosomal compartment may be highly selective. The present observation agrees well with our previous studies on the endosomal proteolysis of internalised human proinsulin (HPI) that show that rat liver endosomes produce selective cleavages in the Glu 33 -Lys 64 C-peptide without apparent modification of arginyl-peptide bonds [6] . Previously, other studies have reported that Triton X-100 solubilised rat liver endosomes [4] and rat hepatoma Fao cells stably transfected with HPI [5] processed HPI to des- [31, 32] -HPI without conversion into mature HI. However, fully processed insulin was identified after transfection of hepatoma cells with the gene encoding rat proinsulin [5] . It has, however, also been reported that mouse serum contains a carboxypeptidase activity, suggested to be carboxypeptidase-N or kininase-I, which converted [Arg ]-HI to HI by sequentially removing Arg 31 and Arg 32 [37] . Thus, the circulating blood may be the physiological locus for the removal of Cterminal Arg residues from arginyl-insulins.
The present study suggests that, besides genetically engineered mutant insulin analogues [14, 24, 26] , incompletely cleaved proinsulin intermediates (in particular Argextended insulins) as well as unprocessed proinsulin [6] may represent potential therapeutic tools to achieve further improvements in glycaemic control during diabetic disease. Moreover, our study has identified endosomal neutral Argaminopeptidase, which acts on internalised arginyl-insulin and modulates insulin signalling at the endosomal locus in conjonction with IDE and cathepsin D, and represents a potential therapeutic target.
